根治性膀胱切除术后变异组织学膀胱癌的肿瘤学监测
本研究基于多机构注册数据,纳入528例变异组织学(VH)膀胱癌和1894例纯尿路上皮癌(pUC)患者,旨在建立动态权衡其他原因死亡(OCM)与复发风险的个性化随访方案。结果显示VH复发风险更高(10年无复发生存率30% vs 51%,p<0.001),中位复发时间更短(88 vs 123个月,p<0.01),且微乳头亚型腹部和肺部复发风险最高。年轻VH患者(<60岁,pT0/Ta/T1/N0)应监测超过10年,而pUC为6.5年。
要点
- VH膀胱癌复发风险高于pUC,10年无复发生存率30% vs 51%。
- 微乳头亚型腹部和肺部复发风险最高,混合亚型骨转移风险最高。
- VH患者(<60岁,pT0/Ta/T1/N0)应监测超过10年,pUC为6.5年。
核心结论
- VH膀胱癌复发风险高于pUC,适用于pUC的随访方案不应用于VH患者。
- 基于年龄、合并症、病理分期和复发部位的个性化监测方案可改善共享决策。
研究设计与样本
- 多机构注册研究,纳入528例VH膀胱癌和1894例pUC患者。
- 采用Weibull回归确定OCM风险超过复发风险的时间点。
- 按年龄和合并症分层OCM风险,按病理分期和复发部位分层复发风险。
主要发现
- VH患者10年无复发生存率30%,pUC为51%(p<0.001)。
- VH患者中位复发时间88个月,pUC为123个月(p<0.01)。
- 微乳头亚型腹部和肺部复发风险最高,混合亚型骨和其他部位转移风险最高。
关键数值与推荐
- VH患者<60岁且pT0/Ta/T1/N0应监测超过10年,pUC为6.5年。
临床怎么用
- 对VH膀胱癌患者应延长监测时间,尤其年轻和早期分期患者。
- 根据变异亚型调整监测部位,微乳头亚型关注腹部和肺部,混合亚型关注骨骼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Presently, major guidelines do not provide specific recommendations on oncologic surveillance for patients who harbor variant histology (VH) bladder cancer (BCa) at radical cystectomy. We aimed to create a personalized followup scheme that dynamically weighs other cause mortality (OCM) vs the risk of recurrence for VH BCa, and to compare it with a similar one for pure urothelial carcinoma (pUC). MATERIALS AND METHODS: Within a multi-institutional registry, 528 and 1,894 patients with VH BCa and pUC, respectively, were identified. The Weibull regression was used to detect the time points after which the risk of OCM exceeded the risk of recurrence during followup. The risk of OCM over time was stratified based on age and comorbidities, and the risk of recurrence on pathological stage and recurrence site. RESULTS: Individuals with VH had a higher risk of recurrence (recurrence-free survival 30% vs 51% at 10 years, p <0.001) and shorter median time to recurrence (88 vs 123 months, p <0.01) relative to pUC. Among VH, micropapillary variant conferred the greatest risk of recurrence on the abdomen and lungs, and mixed variants carried the greatest risk of metastasizing to bones and other sites compared to pUC. Overall, surveillance should be continued for a longer time for individuals with VH BCa. Notably, patients younger than 60 years with VH and pT0/Ta/T1/N0 at radical cystectomy should continue oncologic surveillance after 10 years vs 6.5 years for pUC individuals. CONCLUSIONS: VH BCa is associated with greater recurrence risk than pUC. A followup scheme that is valid for pUC should not be applied to individuals with VH. Herein, we present a personalized approach for surveillance that may allow an improved shared decision.
引用
- Martini A, Afferi L, Zamboni S, et al. Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. J Urol. 2021. PMID: 34032498. doi:10.1097/JU.0000000000001886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。